<div id="readability-page-1"><p>Bio-Techne Corp (NASDAQ:TECH - Get Free Report)'s stock price dropped 10.8% on Wednesday following a weaker than expected earnings announcement. The company traded as low as $49.77 and last traded at $50.5320. Approximately 2,041,218 shares traded hands during trading, a decline of 12% from the average daily volume of 2,317,194 shares. The stock had previously closed at $56.68.</p><ul><li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li></ul><p>The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.08 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The firm's revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. </p><h2>Wall Street Analysts Forecast Growth</h2><p>TECH has been the topic of several research analyst reports. Benchmark  reiterated a &#34;buy&#34; rating on shares of Bio-Techne in a research report on Tuesday, February 3rd. Wells Fargo &amp; Company lifted their price objective on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, February 6th. Zacks Research upgraded shares of Bio-Techne from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 9th. Evercore boosted their price target on shares of Bio-Techne from $62.00 to $68.00 and gave the company an &#34;in-line&#34; rating in a report on Thursday, February 5th. Finally, TD Cowen  restated a &#34;buy&#34; rating on shares of Bio-Techne in a report on Tuesday, March 17th. One investment analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, Bio-Techne currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $72.77.</p><p><b>Read Our Latest Analysis on Bio-Techne</b></p><h2>Institutional Trading of Bio-Techne</h2><p>Several hedge funds have recently modified their holdings of the stock. Asset Management One Co. Ltd. boosted its stake in  Bio-Techne by 2.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 153 shares during the last quarter.  Accredited Investors Inc. raised its holdings in shares of  Bio-Techne by 2.7% during the fourth quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company's stock worth $356,000 after acquiring an additional 161 shares during the period.  Allworth Financial LP increased its stake in  Bio-Techne by 28.4% in the 3rd quarter. Allworth Financial LP now owns 786 shares of the biotechnology company's stock valued at $44,000 after buying an additional 174 shares during the last quarter.  Oppenheimer &amp; Co. Inc. grew its position in shares of  Bio-Techne by 3.5% in the 4th quarter. Oppenheimer &amp; Co. Inc. now owns 5,351 shares of the biotechnology company's stock valued at $315,000 after acquiring an additional 181 shares during the period.  Finally, Angeles Wealth Management LLC lifted its holdings in  Bio-Techne by 3.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 189 shares during the last quarter. 98.95% of the stock is owned by institutional investors. </p><h2>Bio-Techne Stock Down 10.6%</h2><p>The firm has a market cap of $7.92 billion, a P/E ratio of 99.38, a P/E/G ratio of 3.60 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54. The firm's fifty day moving average is $54.70 and its 200 day moving average is $59.71. </p><h2>Bio-Techne Company Profile</h2> (Get Free Report)<p>Bio-Techne Corporation <span>NASDAQ: TECH<span></span></span> is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.  </p><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Bio-Techne</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2><p>Before you consider Bio-Techne, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TECH

<p>Bio-Techne Corp (NASDAQ:TECH) shares fell 10.8% to $50.53 after reporting disappointing earnings, missing EPS estimates by $0.02 and revenue expectations by $4.66 million. The company’s revenue declined 1.5% year-over-year. Analysts maintain a "Moderate Buy" rating with a consensus target price of $72.77. Institutional investors hold 98.95% of the stock. Bio-Techne specializes in life sciences products, including reagents and instruments for research and diagnostics.</p>

Bio-Techne (NASDAQ:TECH) Shares Down 10.8% on Disappointing Earnings